Cubist Systematic Strategies, LLC Biomea Fusion, Inc. Transaction History

Cubist Systematic Strategies, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$4.14 - $15.3 $100,622 - $371,866	24,305 New	24,305 $109,000
Q4 2023 Feb 14, 2024	SELL	$8.37 - $19.8 $308,049 - $728,719	-36,804 Reduced 40.18%	54,791 $795,000
Q3 2023 Nov 14, 2023	BUY	$13.44 - $23.02 $1.23 Million - $2.11 Million	91,595 New	91,595 $1.26 Million
Q3 2022 Nov 14, 2022	BUY	$9.51 - $13.61 $78,400 - $112,200	8,244 Added 40.71%	28,493 $279,000
Q2 2022 Aug 15, 2022	BUY	$3.0 - $12.03 $60,747 - $243,595	20,249 New	20,249 $243,000
Q1 2022 May 16, 2022	SELL	$4.39 - $9.03 $65,753 - $135,251	-14,978 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$7.22 - $12.72 $108,141 - $190,520	14,978 New	14,978 $112,000

104

17.8M

1.68M

410K

Ticker BMEA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,290,600
Market Cap $189M
Description
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in onc...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.